RAPP · smart money activity
Who's buying Rapport Therapeutics, Inc.?
6 insiders bought $1.7M within 14 days, including John Maraganore (Director) and Paul M Silva (Director).
Smart money score94#2 of 372 stocks
Latest filingOct 23, 2026
Independent buyers6
Signal sourcesForm 4
Signals against0
RAPP insider buying, 13F and 13D filings
-
Ramiro Sanchez (Director): Bought $98K on the open market3.6K shares at ~$27.35, traded 2026-10-23. Now holds 3.6K shares (new position).
-
6 insiders: Bought $1.7M on the open market within 14 daysJohn Maraganore (Director); Paul M Silva (Director); Ramiro Sanchez (Director); Steven M Paul (Director); Troy A. Ignelzi (Chief Financial Officer); Wendy B. Young (Director)
-
Paul M Silva (Director): Bought $100K on the open market3.7K shares at ~$27.07, traded 2026-10-22. Now holds 3.7K shares (new position).
-
Wendy B. Young (Director): Bought $100K on the open market3.8K shares at ~$26.39, traded 2026-10-22. Now holds 13.3K shares (stake up 40%).
-
Steven M Paul (Director): Bought $974K on the open market35.7K shares at ~$27.28, traded 2026-10-22. Now holds 77.4K shares (stake up 86%).
-
John Maraganore (Director): Bought $249K on the open market9.4K shares at ~$26.45, traded 2026-10-22. Now holds 9.4K shares (new position).
-
Troy A. Ignelzi (Chief Financial Officer): Bought $144K on the open market5.5K shares at ~$26.10, traded 2026-10-21. Now holds 15.5K shares (stake up 55%).
Signals come from SEC filings: Form 4 (insiders, filed within 2 business days), 13F (fund holdings, up to 45 days after quarter end) and Schedule 13D (5%+ activist stakes). This page reports what the filings show; it is not investment advice.